Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fludarabine

fludarabine

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of fludarabine

275 trials tracked of fludarabine: 21 in phase 3 or 4 and 5 with published results. The most-cited published study has 151 citations.

275Trials tracked
21Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 2 Phase 3 19 Phase 2 218 Phase 1 23 Other / NA 13
  1. Phase 3 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed · 151 cited
  2. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 111 cited
  3. Phase 3 TBI Dose De-escalation for Fanconi Anemia Completed · 109 cited
  4. Phase 3 Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Completed · 55 cited
  5. Phase 3 A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia Completed · 35 cited
  6. Phase 4 Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting Completed
Show 44 more trials
  1. Phase 4 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed
  2. Phase 3 Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients Completed
  3. Phase 3 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Completed
  4. Phase 3 IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Completed
  5. Phase 3 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Completed
  6. Phase 3 Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Completed
  7. Phase 3 Stem Cell Transplantation for Sickle Cell Anemia Completed
  8. Phase 3 Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A Completed
  9. Phase 3 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Completed
  10. Phase 3 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Completed
  11. Phase 3 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia Completed
  12. Phase 3 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed
  13. Phase 3 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed
  14. Phase 3 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  15. Phase 3 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Completed
  16. Phase 2 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed
  17. Phase 2 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed
  18. Phase 2 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed
  19. Phase 2 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed
  20. Phase 2 Autologous and Allogeneic Transplant for Relapsed Lymphoma Completed
  21. Phase 2 A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) Completed
  22. Phase 2 Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  23. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  24. Phase 2 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Completed
  25. Phase 2 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders Completed
  26. Phase 2 Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Completed
  27. Phase 2 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed
  28. Phase 2 Off-the-shelf NK Cells + SCT for Myeloid Malignancies Completed
  29. Phase 2 Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Completed
  30. Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed
  31. Phase 2 Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed
  32. Phase 2 Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients Completed
  33. Phase 2 Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome Completed
  34. Phase 2 Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Completed
  35. Phase 2 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed
  36. Phase 2 CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy Completed
  37. Phase 2 Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer Completed
  38. Phase 2 Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Completed
  39. Phase 2 Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders Completed
  40. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  41. Phase 2 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Completed
  42. Phase 2 Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma Completed
  43. Phase 2 Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Completed
  44. Phase 2 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed

Showing the 50 most-cited and recently-updated of 275 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of fludarabine cellular pharmacology shows up to 14.5-fold exposure variability in hematological malignancy patients
Drug Pipeline Sys. Review
Review of fludarabine cellular pharmacology shows up to 14.5-fold exposure variability in hematological malignancy patients Drug exposure varies wildly in patients receiving fludarabine for blood cancers
This review examines fludarabine cellular pharmacology, specifically transport and metabolism, in patients receiving the medication for hema…
Drug exposure varies up to 14.5-fold between patients receiving fludarabine, directly linking low levels to treatment failure and death.
Frontiers May 19, 2026
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Oncology RCT
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Apr 28, 2026
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Oncology Phase II
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
CT.gov Apr 13, 2026
Phase 1 trial of off-the-shelf NK cell therapy shows no DLTs or responses in relapsed/refractory AML
Oncology Phase I
Phase 1 trial of off-the-shelf NK cell therapy shows no DLTs or responses in relapsed/refractory AML A Safer, Ready-to-Use Cell Therapy Takes Aim at Tough Leukemia
A single-arm, open-label, dose-escalation Phase 1 trial enrolled 6 adults with relapsed/refractory AML who received SAR445419, an off-the-sh…
A new, ready-to-use cell therapy proved safe in a first human trial for aggressive leukemia, offering hope for patients who have run out of …
Apr 12, 2026